3320:HKEXChina Resources Pharmaceutical Group Ltd. Analysis

Cross Plus Inc. trades at ¥1,308, comfortably below its 20‑day (¥1,314.5), 50‑day (¥1,345.96) and 200‑day (¥1,339.02) simple moving averages, signaling a short‑term pull‑back within a neutral overall trend. The MACD histogram has turned positive (≈+1.8) while the MACD line sits above its signal, providing a bullish technical cue. RSI sits at 44, indicating the stock is not yet oversold nor overbought, and price remains above the identified support at ¥1,274, giving a cushion against further downside. On the valuation side, the stock's PE of 5.6 and PB of 0.5 are markedly low, and a discounted cash‑flow model suggests a fair value of ¥1,427, implying ~9% upside. The dividend yield of 4.59% is attractive, with a modest 21% payout ratio and solid operating cash flow, supporting dividend sustainability. Volatility over the past 30 days is ~14%, beta is only 0.23, and volume is stable, pointing to a low‑risk profile despite modest revenue contraction.
Fundamentally, revenue has slipped 6% year‑over‑year and operating margin is slightly negative, but net profit margin remains positive at 2.9% and ROE is near 10%, indicating some earnings resilience. The consumer‑cyclical apparel sector is sensitive to economic cycles, yet the company’s diversified product mix and strong dividend make it a defensive play. Given the undervalued pricing, solid dividend, and low systematic risk, the stock appears positioned for a gradual price recovery toward its DCF target, provided operating efficiencies improve.